David Liu - Protagonist Therapeutics Executive
| PTGX Stock | USD 45.53 0.93 2.00% |
Executive
Dr. David Y. Liu, Ph.D., serves as Chief Scientific Officer, Head of Research Development of the Company. Dr. Liu has served as the Company Chief Scientific Officer since May 2013 and has served as CSO and Head of Research and Development since February 2016. Prior to Protagonist, Dr. Liu was the Chief Operating Officer and a cofounder of Trenovus, Inc., from 2010 to 2012. Prior to Trenovus, Dr. Liu was Vice President of Research at FibroGen Inc., from 2002 to 2010. Prior to Fibrogen, Dr. Liu served as Director of Inflammation Research at Scios, Inc., now part of Johnson Johnson, from 1992 to 2002. Dr. Liu held a position as an academic researcher at Brigham and Women Hospital, Harvard Medical School and was Instructor and Assistant Professor in the Department of Medicine, Harvard Medical School, from 1976 to 1986 since 2016.
| Age | 74 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160 |
| Phone | 510 474 0170 |
| Web | https://www.protagonist-inc.com |
David Liu Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Liu against Protagonist Therapeutics stock is an integral part of due diligence when investing in Protagonist Therapeutics. David Liu insider activity provides valuable insight into whether Protagonist Therapeutics is net buyers or sellers over its current business cycle. Note, Protagonist Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Protagonist Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Liu over a year ago Bona fide gift to David Liu of 1000000 shares of Prime Medicine subject to Section 16 |
Protagonist Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1996 % which means that it generated a profit of $0.1996 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4097 %, meaning that it created $0.4097 on every $100 dollars invested by stockholders. Protagonist Therapeutics' management efficiency ratios could be used to measure how well Protagonist Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.29 in 2024. Total Assets is likely to drop to about 204.1 M in 2024. Net Tangible Assets is likely to drop to about 141.3 M in 2024Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| RPh Young | Seres Therapeutics | 57 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Lisa MD | Seres Therapeutics | 65 | |
| MD FAAP | Lumos Pharma | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| JD Esq | Seres Therapeutics | 69 | |
| David Ege | Seres Therapeutics | 49 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Nicole Esq | HCW Biologics | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| MD MBA | Eliem Therapeutics | 50 | |
Management Performance
Protagonist Therapeutics Leadership Team
Elected by the shareholders, the Protagonist Therapeutics' board of directors comprises two types of representatives: Protagonist Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagonist. The board's role is to monitor Protagonist Therapeutics' management team and ensure that shareholders' interests are well served. Protagonist Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagonist Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mohammad Masjedizadeh, Executive Officer | ||
| Abha Bommireddi, Executive Management | ||
| Matthew JD, Executive Counsel | ||
| Ashok Bhandari, Vice President - Chemistry | ||
| Matthew Gosling, Executive Counsel | ||
| Richard Shames, Chief Medical Officer | ||
| Dinesh Patel, President CEO, Director | ||
| David Liu, Chief Scientific Officer, Head of Research & Development | ||
| Carena Spivey, Senior Resources | ||
| Suneel Gupta, Executive Vice President of Clinical Operations and Clinical Pharmacology | ||
| Mark Smythe, Vice President -Technology & Alliances | ||
| Scott MD, Executive Gastroenterology | ||
| FACP MD, Chief Officer | ||
| Carter King, Executive Development | ||
| Asif Ali, Executive Officer |
Protagonist Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protagonist Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.41 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.53 % | ||||
| Operating Margin | (8.87) % | ||||
| Current Valuation | 2.31 B | ||||
| Shares Outstanding | 59.6 M | ||||
| Shares Owned By Insiders | 1.17 % | ||||
| Shares Owned By Institutions | 98.83 % | ||||
| Number Of Shares Shorted | 3.28 M | ||||
| Price To Earning | (4.81) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.